Moderna-Merck Cancer Vaccine Crushes Late-Stage Trial Results
A Moderna-Merck combo regimen outperformed Keytruda alone in melanoma, sending both stocks surging on promising Phase 3 data.
If you're holding Moderna or Merck, today's a good day. The two companies just dropped Phase 3 data showing their experimental cancer vaccine combination meaningfully extended how long melanoma patients went without their disease coming back — and that's the kind of readout that moves markets.
The key metric here is recurrence-free survival. The combo regimen — pairing Moderna's mRNA-based personalized cancer vaccine with Merck's blockbuster immunotherapy Keytruda — beat Keytruda flying solo. That's not a small hurdle. Keytruda is already one of the most widely used cancer drugs on the planet, so outperforming it is a serious signal.
Read more Chip Costs Are Handing Apple and Samsung a Win in India →
This is late-stage data, which means it carries real weight. Early trials get ignored all the time. Phase 3 is where careers and drug approvals are made. Investors clearly got the memo — both stocks soared on the news, reflecting genuine confidence that this combo could eventually reshape how doctors treat melanoma and potentially other cancers down the line.
The mRNA angle is worth watching closely. Moderna built its name on mRNA technology during COVID, and this trial is a proof-of-concept that the platform has legs far beyond vaccines for infectious disease. Personalized cancer vaccines — tuned to an individual patient's tumor — have long been the dream, and this data pushes that dream closer to reality.
Traders and long-term investors alike should keep this one on the radar. Regulatory conversations are the next catalyst. Continue reading at US Top News and Analysis.
